"As of Dec. 31, Pfizer had three oncology blockbusters, including its top-selling breast cancer drug Ibrance, which brought in $4.7 billion in sales last year, and prostate cancer drug Xtandi. Sales of both drugs were down in 2023, and both are expected to lose key patent protections in 2027. "

good timing for a deal  if the Zen 3694 combo with Xtandi trial move forward